Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zepbound
Biotech
Lilly's obesity pill maintains weight lost on injectable GLP-1s
Patients maintained most of their weight loss after switching from injectable GLP-1s, teeing Lilly up to target people taking Novo Nordisk’s Wegovy.
Nick Paul Taylor
Dec 18, 2025 8:20am
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Aug 7, 2025 6:30am
Scholar Rock's SMA drug helps Zepbound patients retain muscle
Jun 18, 2025 9:10am
Lilly's amylin data impress with 11% weight loss, tolerability
Jun 16, 2025 4:55am
Novo plots ph. 3 trials for next-gen obesity asset amycretin
Jun 13, 2025 10:35am
Amgen’s late-stage obesity trials expected to read out in ‘27
Mar 5, 2025 1:58pm